Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05144880
Other study ID # 2020YKJ08
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 1, 2021
Est. completion date December 30, 2024

Study information

Verified date January 2023
Source Zhejiang Chinese Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Two groups of subjects will be included 55 subjects in electroacupuncture with 2Hz group, 55 subjects in the electroacupuncture with 100Hz group. The clinical efficacy of electroacupuncture with different frequencies (2 Hz, 100 Hz) in the treatment of MDD will be observed by evaluation indicators, such as Self-rating depression scale and Hamilton depression scale.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 110
Est. completion date December 30, 2024
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Patients su?ering from MDD in accordance with the diagnostic criteria; 2. Hamilton Depression Scale score is between 21 and 35 (mild to moderate MDD); 3. 18=age=60 years, both gender; 4. Patients who have not used antidepressants and other psychiatric drugs (including traditional Chinese medicine), or have used them but have stopped for at least 2 weeks; 5. Patients have clear consciousness and could communicate with others normally; 6. Patients could understand the full study protocol and written informed consent is provided by themselves. Note: Subjects who meet the above six items will be included. Exclusion Criteria: 1. Patients with bipolar disorder; 2. Patients with schizophrenia or other mental disorders; 3. Patients with severe medical diseases, tumors or diseases of the central nervous system; 4. Patients su?ering from severe depressive episode with psychotic symptoms; 5. Suicidal patients; 6. Patients with seasonal depression; 7. Patients with organic depression; 8. Patients with alcohol or drug addicts; 9. Patients using other therapies; 10. Patients in pregnancy or lactation; 11. Patients suffering from cognitive dysfunction, aphasia or other diseases that cannot cooperate with treatment; 12. Patients with pacemakers; 13. Patients who are not suitable for electroacupuncture.

Study Design


Intervention

Other:
electroacupuncture
A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.

Locations

Country Name City State
China Xiaoyu Li Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Chinese Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in anxiety and depression severity measure by Self-rating depression scale(SDS) This scale contains 20 items that reflect the subjective feelings of depression, 10 of which are positive scores and 10 are reverse scores. Each item is divided into four grades according to the frequency of symptoms, If it is a positive scoring question, it will be rated as 1, 2, 3, and 4 points; for a reverse scoring question, it will be rated as 4, 3, 2, and 1. After the evaluation, add up the scores in the 20 items to get the total rough score, and then multiply the rough score by 1.25 and take the integer part to get the standard score There will be evaluated before intervention, at 2, 4weeks after intervention and at the end of 4-weeks follow-up.
Primary Change in the severity of depression measure by Hamilton depression scale (HAMD) This scale is performed by two trained raters to perform a HAMD, usually in the form of conversation and observation. After the examination, the two raters will score independently There will be evaluated before intervention, at 2, 4weeks after intervention and at the end of 4-weeks follow-up.
Secondary Change in sleep quality measured by Insomnia severity index (ISI) There will be evaluated before intervention, at 2, 4weeks after intervention and at the end of 4-weeks follow-up.
Secondary Change in Traditional Chinese medicine syndrome score There will be evaluated before intervention, at 2, 4weeks after intervention and at the end of 4-weeks follow-up.
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A